Welcome to our dedicated page for Aeterna Zentaris news (Ticker: AEZS), a resource for investors and traders seeking the latest updates and insights on Aeterna Zentaris stock.
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZS) is a global biopharmaceutical company specializing in endocrine therapy and oncology. With a robust track record in drug discovery, development, and commercialization, the company focuses on addressing significant unmet medical needs. Aeterna Zentaris' flagship product, macimorelin (marketed as Macrilen® in the U.S. and Ghryvelin™ in Europe), is the first and only FDA and European Commission-approved oral test for diagnosing adult growth hormone deficiency (AGHD). The company is actively pursuing the extension of macimorelin’s application for diagnosing childhood-onset growth hormone deficiency (CGHD), with the Phase 3 DETECT trial nearing completion.
Recently, Aeterna Zentaris announced a definitive agreement to merge with Ceapro Inc. The merger, expected to close in the second quarter of 2024, aims to leverage Ceapro's revenue-generating cosmeceutical and nutraceutical products, such as oat beta glucan and avenanthramides. The combined entity is poised to generate stable cash flow, diversify its product pipeline, enhance research and development capabilities, and strengthen its market presence in both North America and Europe.
The company remains committed to developing an array of therapeutic assets, including treatments for neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism, and amyotrophic lateral sclerosis (ALS). Aeterna Zentaris is well-capitalized, with a strategic plan to advance innovative products and deliver sustained value to its shareholders.
Aeterna Zentaris reported a net loss of $2.6 million for Q1 2022, compared to $1.5 million in Q1 2021. Revenues decreased to $1.5 million from $1.7 million year-over-year. The company ended the quarter with $63.6 million in cash, expected to fund operations through 2023. Aeterna highlighted progress in its AIM Biologicals programs for treating Parkinson's and neuromyelitis optica spectrum disorder, with upcoming presentations at scientific conferences. The company also secured a European patent for macimorelin across 27 countries.
Aeterna Zentaris Inc. (NASDAQ: AEZS) announced that pre-clinical study results of its AIM Biologicals for Parkinson's Disease (PD) were accepted for presentation at IMMUNOLOGY2022. The studies, featuring α-synuclein peptides, show potential in preventing neuron loss in an animal model of PD. The presentation will be led by Prof. Joerg Wischhusen at the Oregon Convention Center on May 6-7, 2022. Aeterna aims to explore AIM Biologicals' therapeutic potential, supported by positive pre-clinical results indicating mobility improvements and neuron rescue in treated PD mice.
Aeterna Zentaris has strengthened its intellectual property portfolio by securing a European patent for macimorelin, the active ingredient in Ghryvelin® / Macrilen™, across 27 EU countries and the UK and Turkey. This patent, extending until 2038, protects the use of macimorelin for diagnosing adult growth hormone deficiency (GHD). The company aims to enhance protection by entering the national phase in 41 European countries, benefiting its licensing partner, Consilient Health. Macimorelin is the only FDA and European Commission approved oral diagnostic for GHD.
JTC Team continues its Virtual Investor Spotlight Series on April 14, 2022, featuring presentations from Aeterna Zentaris (NASDAQ:AEZS), CNS Pharmaceuticals (NASDAQ:CNSP), and American Resources Corporation (NASDAQ:AREC). The series highlights Aeterna's pre-clinical pipeline addressing unmet medical needs, CNS's advancements in treating Glioblastoma, and discussions on national security regarding rare earth elements with American Resources. Live webcasts will be available, providing insights into these companies and their ongoing projects.
Aeterna Zentaris (NASDAQ: AEZS), a biopharmaceutical company, will host a live moderated video webcast featuring CEO Dr. Klaus Paulini and CFO Giuliano La Fratta on April 14, 2022, at 10:00 AM ET. The event will cover the company’s pre-clinical pipeline, targeting conditions like neuromyelitis optica, Parkinson's disease, and amyotrophic lateral sclerosis. A key highlight includes a discussion on an oral vaccine for SARS-CoV-2. The event can be accessed through the company’s website, with a replay available after the presentation.
Aeterna Zentaris Inc. (NASDAQ: AEZS) announced that their AIM Biologicals for neuromyelitis optica spectrum disorder (NMOSD) has been accepted for presentation at the 13th International Congress on Autoimmunity in Athens, Greece, from June 10-13, 2022. The research, presented by Dr. Valentin Bruttel, highlights the potential of AIM Biologicals in inducing specific regulatory T cells, showcasing promising pre-clinical results. NMOSD is a serious CNS disorder affecting roughly 10,000 to 15,000 patients in the U.S. and Europe, with a critical need for new therapeutic options.
Aeterna Zentaris Inc. (NASDAQ: AEZS) reported financial results for the year ended December 31, 2021, revealing a consolidated net loss of $8.4 million, or $0.07 per share, compared to a loss of $5.1 million in 2020. The company's total revenue increased to $5.3 million, up from $3.7 million, primarily driven by development service growth. Aeterna ended the year with $65.3 million in cash, expected to fund operations through 2023. The company is advancing a diversified pipeline, including new therapies for neuromyelitis optica and Parkinson's disease, and a COVID-19 vaccine in development.
Aeterna Zentaris has initiated its pivotal Phase 3 safety and efficacy study, AEZS-130-P02, for macimorelin, aimed at diagnosing childhood-onset growth hormone deficiency (CGHD). The study, part of the Pediatric Investigation Plan agreed with regulatory agencies, plans to enroll approximately 100 participants aged 2 to 18 years. With patient enrollment on track for this quarter, completion of the study is anticipated in Q3 2022. Positive preliminary results from a previous study indicate a favorable pharmacokinetic profile for macimorelin.
Aeterna Zentaris Inc. (NASDAQ: AEZS) announced that CEO Dr. Klaus Paulini will present at the Q2 Virtual Investor Summit on May 17, 2021 at 8:45 AM ET. The event will include a live video webcast accessible on the Company's website. Management will also hold one-on-one virtual meetings with registered investors. Aeterna is a biopharmaceutical company focused on unmet medical needs, with its lead product macimorelin, the only approved oral test for adult growth hormone deficiency. The company is advancing a pipeline addressing various conditions.
Aeterna Zentaris has announced the selection of AEZS-150 as the lead candidate for its delayed clearance parathyroid hormone (PTH) program in collaboration with the University of Sheffield. This candidate aims to provide a new treatment option for primary hypoparathyroidism.
The company is moving into formal preclinical development, with plans for an IND filing for first-in-human studies. AEZS-150 aims for self-administration via a pen, helping patients maintain normal calcium and phosphate levels.
FAQ
What is the current stock price of Aeterna Zentaris (AEZS)?
What is the market cap of Aeterna Zentaris (AEZS)?
What is Aeterna Zentaris Inc. focused on?
What is macimorelin?
What recent merger has Aeterna Zentaris announced?
What are some products offered by Ceapro?
What is the significance of the DETECT trial?
What therapeutic areas is Aeterna Zentaris developing products for?
What are the financial conditions of Aeterna Zentaris?
What strategic advantages will the merger with Ceapro bring?
What are the anticipated benefits of the combined company post-merger?
Where can I find more information about Aeterna Zentaris?
